Search
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with … [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids.
Eteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.
Synonyms: N-dimethylphosphonamidate) RNA, dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,Sodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedIt is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. … The extent of this reaction is dependent on the activity of serum alkaline phosphatases.
Mixtures: OLICLINOMEL N4-550 E EMULSION FOR INFUSION, OLICLINOMEL N7-1000 E EMULSION FOR INFUSIONCefoxitin
go.drugbank.com/drugs/DB01331ApprovedInvestigationalIt is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.
Dextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThyroxine is released from thyroglobulin by proteolysis and secreted into the blood. … Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.
Synonyms: O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosineRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative.
Categories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorVitamin D
go.drugbank.com/drugs/DB11094ApprovedInvestigationalNutraceuticalVet approvedSince vitamin D can be endogenously synthesized in adequate amounts by most mammals exposed to sufficient quantities of sunlight, vitamin D functions like a hormone on vitamin D receptors to regulate calcium … When non-specific references are made about 'vitamin d', the references are usually about the use of vitamin D3 and/or D2.
Mixtures: Super Daily No 2, Multi Nt-OXSynonyms: Vitamin D NOSCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries. … A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617] … cells to promote T cell–mediated cytotoxicity.